At 29.3% CAGR, Asia Pacific Cell and Gene Therapy Market is Projected to be Worth US$ 8,012.75 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031, registering a CAGR of 29.3% from 2023 to 2031. Strategic initiatives by companies and rapid popularity of outsourcing cell and gene therapy manufacturing are among the critical factors attributed to drive the Asia Pacific cell and gene therapy market growth.

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and monitoring of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual and open manufacturing method, as well as building a more commercially suitable process, can be challenging. Therefore, these manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs support product development, manufacturing, clinical trials, and commercialization services to cell and gene therapy companies on a contract basis. Under the partnership with a CDMO, cell and gene therapy manufacturers support scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. Outsourcing cell and gene therapy manufacturing to CDMOs proves to be cost-effective for manufacturers. They gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the Asia Pacific cell and gene therapy market growth.

On the flip side, high cost of cell and gene therapy manufacturing hampers the growth of Asia Pacific cell and gene therapy market.

Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 66.8% market share in 2023, amassing US$ 684.33 million. It is projected to garner US$ 6,007.60 million by 2031 to register 31.2% CAGR during 2023-2031. Furthermore, the cell therapy segment is subcategorized into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is bifurcated into non-viral vectors and viral vectors.

In terms of services, the Asia Pacific cell and gene therapy market is segmented into process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held 42.1% share of Asia Pacific cell and gene therapy market in 2023, amassing US$ 431.67 million. It is anticipated to garner US$ 4,098.47 million by 2031 to expand at 32.5% CAGR during 2023-2031.

By scale, the Asia Pacific cell and gene therapy market is divided into pre-commercial/ R and D manufacturing and commercial scale manufacturing. The pre-commercial/ R and D manufacturing segment held 65.3% share of Asia Pacific cell and gene therapy market in 2023, amassing US$ 668.71 million. It is projected to garner US$ 5,470.61 million by 2031 to expand at 30.0% CAGR from 2023 to 2031.

By end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held 51.0% share of Asia Pacific cell and gene therapy market in 2023, amassing US$ 522.34 million. It is estimated to garner US$ 3,641.16 million by 2031 to expand at 27.5% CAGR during 2023-2031.

Based on country, the Asia Pacific cell and gene therapy market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 37.3% share of Asia Pacific cell and gene therapy market in 2023. It was assessed at US$ 381.89 million in 2023 and is likely to hit US$ 3,136.96 million by 2031, registering a CAGR of 30.1% during 2023-2031.

Key players operating in the Asia Pacific cell and gene therapy market are Catalent Inc., Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd, among others.

• In February 2024, Novo Holdings has entered an agreement to acquire Catalent, Inc. under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com